Metabolic Syndrome;Le syndrome métabolique

Nutrition Clinique et Metabolisme

Volumn 20, Issue 2, 2006, Pages 114-117

  Delarue, Jacques ^a   Allain, Gwenola ^a   Guillerm, Sophie ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Central obesity; Dyslipidermia; Insulin resistance; Physical exercise

Indexed keywords

FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ARTICLE; EXERCISE; FRANCE; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; STRESS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 33745389218     PISSN: 09850562     EISSN: 17683092     Source Type: Journal    
DOI: 10.1016/j.nupar.2006.04.007     Document Type: Article

References (40)

1. Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
2. Alberti K.G., Zimmet P., Shaw J., and IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet 366 (2005) 1059-1062
3. Cameron A.J., Shaw J.E., and Zimmet P.Z. The metabolic syndrome: prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 33 (2004) 351-375
4. Ford E.S., Giles W.H., and Mokdad A.H. Increasing prevalence of the metabolic syndrome among u.s. Adults Diabetes Care 27 (2004) 2444-2449
5. Eisenmann J.C. Secular trends in variables associated with American children and adolescents: a review and synthesis. Am. J. Hum. Biol. 15 (2003) 15786-15794
6. Balkau B., Vernay M., Mhamdi L., Novak M., Arondel D., Vol S., et al. DESIR study group. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French DESIR study. Diabetes Metab. 29 (2003) 526-532
7. Bauduceau B., Baigts F., Bordier L., Burnat P., Ceppa F., Dumenil V., et al. Epimil group. Epidemiology of the metabolic syndrome in 2045 French military personnel (EPIMIL study). Diabetes Metab. 31 (2005) 353-359
8. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the United States. Diabetes Care. 28 (2005) 2745-2749
9. Chandola T., Brunner E., and Marmot M. Chronic stress at work and the metabolic syndrome: prospective study. BMJ 332 (2006) 521-525
10. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 30 (2005) 1-10
11. Wajchenberg B.L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 21 (2000) 697-738
12. Cadoudal T., Leroyer S., Reis A.F., Tordjman J., Durant S., Fouque F., et al. Proposed involvement of adipocyte glyceroneogenesis and phosphoenolpyruvate carboxykinase in the metabolic syndrome. Biochimie 87 (2005) 27-32
13. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes. Res. 11 (2003) 1278-1289
14. Ceriello A., and Motz E. Is oxidative stress the pathogenic mechanism underlying Insulin resistance, diabetes, and cardiovascular disease? The Common Soil Hypothesis Revisited. Arterioscler Thromb. Vasc. Biol. 24 (2004) 816-823
15. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?. Diabetes 52 (2003) 1-8
16. Robertson R.P., Harmon J., Tran P.O., and Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53 Suppl. 1 (2004) S119-S124
17. Sjoholm A., and Nystrom T. Endothelial inflammation in insulin resistance. Lancet 365 (2005) 610-612
18. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84 (2004) 1381-1478
19. Tappy L. Metabolic consequences of overfeeding in humans. Curr. Opin. Clin. Nutr. Metab. Care 7 (2004) 623-628
20. Reaven G.M. Importance of identifying the overweight patient who will benefit the most by losing weight. Ann. Intern. Med. 138 (2003) 420-423
21. Reaven G.M. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr. 25 (2005) 391-406
22. Stone N.J. Focus on lifestyle change and the metabolic syndrome. Endocrinol. Metab. Clin. North Am. 33 (2004) 493-508
23. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes Study. Diabetes Care 20 (1997) 537-544
24. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Diabetes prevention program research group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
25. Tuomilehto J., Lindstrom J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Finnish diabetes prevention study group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344 (2001) 1343-1350
26. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
27. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., and Rossner S. RIO-Europe study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
28. Shadid S., and Jensen M.D. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26 (2003) 3148-3152
29. Miyazaki Y., Mahankali A., Matsuda M., Mahankali S., Hardies J., Cusi K., et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87 (2002) 2784-2791
30. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr. Opin. Cardiol. 21 (2006) 1-6
31. Tenkanen L., Manttari M., Kovanen P.T., Virkkunen H., and Manninen V. Gemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart Study. Arch. Intern. Med. 166 (2006) 743-748
32. Robins S.J., Rubins H.B., Faas F.H., Schaefer E.J., Elam M.B., Anderson J.W., et al. Veterans affairs HDL intervention trial (VA-HIT). Insulin resistance and cardiovascular events with low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Diabetes Care 26 (2003) 1513-1517
33. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis fromthe Department of veterans affairs high-density lipoprotein intervention trial(VA-HIT). Arch. Intern. Med. 162 (2002) 2597-2604
34. Tenenbaum A., Fisman E.Z., Boyko V., Benderly M., Tanne D., Haim M., et al. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch. Intern. Med. 166 (2006) 737-741
35. Delarue J., Chang-Hong L., Richard C., Charlotte C., and Brigitte S. Interaction of fish oil and a glucocorticoid on metabolic responses to an oral glucose load in healthy human subjects. Br. J. Nutr. 95 (2006) 267-272
36. Delarue J., LeFoll C., Corporeau C., and Lucas D. N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?. Reprod. Nutr. Dev. 44 (2004) 289-299
37. Delarue J., Matzinger O., Binnert C., Schneiter P., Chiolero R., and Tappy L. Fish oil prevents the adrenal activation elicited by mental stress in healthy men. Diabetes Metab. 29 (2003) 289-295
38. Ebbesson S.O., Risica P.M., Ebbesson L.O., Kennish J.M., and Tejero M.E. Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. Int. J. Circumpolar Health 64 (2005) 396-408
39. Lombardo Y.B., and Chicco A.G. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J. Nutr. Biochem. 17 (2006) 1-13
40. Brady L.M., Lovegrove S.S., Lesauvage S.V., Gower B.A., Minihane A.M., Williams C.M., et al. Increased n-6 polyunsaturated fatty acids do not attenuate the effects of long-chain n-3 polyunsaturated fatty acids on insulin sensitivity or triacylglycerol reduction in Indian Asians. Am. J. Clin. Nutr. 79 (2004) 983-991